➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Medtronic
Merck
Johnson and Johnson
Harvard Business School
Boehringer Ingelheim

Last Updated: September 28, 2020

DrugPatentWatch Database Preview

Patent: 9,168,262

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,168,262
Title:Estriol therapy for multiple sclerosis and other autoimmune diseases
Abstract: The present invention discloses administering steroid hormones to mammals to treat autoimmune related diseases, more particularly, Th1-mediated (cell-mediated) autoimmune diseases including: multiple sclerosis (MS), rheumatoid arthritis (RA), autoimmune thyroiditis and uveitis. Most preferably the invention is used to treat a patient with a therapeutically effective amount of estriol of 8 milligrams once daily via oral administration to treat the symptoms or prevent the onset of multiple sclerosis.
Inventor(s): Voskuhl; Rhonda R. (Los Angeles, CA)
Assignee: The Regents of the University of California (Oakland, CA)
Application Number:13/763,814
Patent Claims:see list of patent claims

Details for Patent 9,168,262

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Bayer Healthcare Pharms BETASERON interferon beta-1b VIAL; SUBCUTANEOUS 103471 001 1993-07-23   Start Trial The Regents of the University of California (Oakland, CA) 2021-04-25 RX Orphan search
Biogen AVONEX interferon beta-1a VIAL 103628 001 1996-05-17   Start Trial The Regents of the University of California (Oakland, CA) 2021-04-25 RX search
Serono Inc REBIF interferon beta-1a SYRINGE 103780 001 2002-03-07   Start Trial The Regents of the University of California (Oakland, CA) 2021-04-25 RX search
Serono Inc REBIF interferon beta-1a SYRINGE 103780 002 2002-03-07   Start Trial The Regents of the University of California (Oakland, CA) 2021-04-25 RX search
Novartis Pharms EXTAVIA interferon beta-1b INJECTABLE; SUBCUTANEOUS 125290 001 2009-08-14   Start Trial The Regents of the University of California (Oakland, CA) 2021-04-25 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Colorcon
McKesson
Baxter
Harvard Business School
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.